Jun 29 2012
A.P.
Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company,
today announced additional data from the Company's Phase 3 study of
APF530 for the prevention of chemotherapy-induced nausea and vomiting
(CINV). The findings from the analysis of this subset of data indicate
that APF530 offered comparable nausea control and patient satisfaction
to palonosetron (Aloxi®) over a 5-day period. The Company presented the
study results today at a poster presentation during the Multinational
Association of Supportive Care in Cancer and the International Society
of Oral Oncology (MASCC/ISOO) International Symposium in New York.
As previously reported, the Phase 3 study showed APF530 was comparable
to palonosetron in preventing both acute- and delayed-onset CINV in
patients receiving either moderately emetogenic chemotherapy (MEC) or
highly emetogenic chemotherapy (HEC).
"Delayed-onset nausea and vomiting remains a major issue associated with
many cancer treatment options, which can affect a patient's quality of
life as well as his or her ability to sustain the recommended
potentially lifesaving chemotherapy regimen," said Rebecca A.
Clark-Snow, RN, BSN, OCN, clinical nurse coordinator and chair of the
MASCC Antiemetic Study Group. "In particular, patients who have
experienced nausea and vomiting during previous chemotherapy treatments
are more susceptible to experiencing a recurrence during subsequent
therapy. These data indicate that APF530 has the potential to be a
promising therapy option for physicians and patients."